Advertisement

Topics

AbbVie’s pan-genotypic hep C therapy cleared in the US

04:03 EDT 4 Aug 2017 | PharmaTimes

AbbVie’s hepatitis C therapy Mavyret has picked up an approval in the US just days after having been green lighted by regulators in Europe.

Original Article: AbbVie’s pan-genotypic hep C therapy cleared in the US

NEXT ARTICLE

More From BioPortfolio on "AbbVie’s pan-genotypic hep C therapy cleared in the US"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...